Deutsche Bank lowered the firm’s price target on Genmab to DKK 2,500 from DKK 2,750 and keeps a Buy rating on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
- Genmab’s TEPKINLY Gains EU Approval for Lymphoma
- Genmab downgraded to Neutral from Overweight at JPMorgan
- AbbVie announces European Commission approval for Tepkinly for second indication
- TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma